01/08/2026 | Press release | Distributed by Public on 01/08/2026 08:44
Our Capital Markets Advisor, Sanjeev Srivastava, was interviewed by Maxine Hoover from The Beryl Consulting Group at the Beryl Elites' Investment Conference in New York City:
"Biomanufacturing is going through its ChatGPT moment. The reason for that is, that eXoZymes has the technology to make enzymes function outside of cells. I know that sounds a bit technical, but what that means is that many medicines, nutraceuticals, and other chemicals, can be made much more cost-effective and in a way that nature could not provide - it was impossible to get these products. This is a very exciting time for the industry!"
eXoZymes Safe Harbor
This video includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this video regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations